Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2201359 | 0.83 | CXCR4 (0.47) | KMT2AMEN1CXCR4LMNA | |
| SCHEMBL2201582 | 0.83 | CXCR4 (0.47) | KMT2AMEN1CXCR4LMNA | |
| SCHEMBL2206056 | 0.82 | CXCR4 (0.54) | CXCR4 | |
| SCHEMBL2202937 | 0.79 | CXCR4 (0.38) | CXCR4 | |
| SCHEMBL2202949 | 0.79 | CXCR4 (0.38) | CXCR4 | |
| SCHEMBL12426518 | 0.79 | CXCR4 (0.49) | KMT2AMEN1CXCR4 | |
| SCHEMBL1638428 | 0.76 | DRD4 (0.52) | KMT2AMEN1CXCR4NPC1 | |
| SCHEMBL2200590 | 0.76 | RORC (0.34) | KMT2A | |
| SCHEMBL2201589 | 0.75 | CXCR4 (0.47) | KMT2AMEN1CXCR4OPRK1 | |
| Hydrochloric Acid SCHEMBL2202811 | 0.75 | KMT2A (0.34) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977512-B2 | Amine derivative, and production method and use thereof | KUREHA CORPORATION (JP) | 2011-07-12 | — | — | US | disclosed |
| US-20080293951-A1 | Amin Derivative, and Production Method and Use Thereof | KUREHA CORPORATION | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293951-A1 | Amin Derivative, and Production Method and Use Thereof | BCAT2, BCAT1, MRPL9 | KMT2A 2823/4885MEN1 1672/4885CXCR4 2546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.